+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The treatment of hypercholesterolemia with beta-pyridylcarbinol. Part 5. Report on 16 cases with severe hypercholesterolemia treated for 12 years

The treatment of hypercholesterolemia with beta-pyridylcarbinol. Part 5. Report on 16 cases with severe hypercholesterolemia treated for 12 years

Atherosclerosis 26(4): 611-615

A group of 78 patients with severe hypercholesterolemia (-X = 464 mg/dl) and symptoms of vascular disease of the heart, the extremities, or the brain, started a beta-pyridylcarbinol treatment with an average daily dosage of 1.2 g in 1964. In 1976 we could re-examine 12 patients, still on the same therapy. No myocardial infarction has occurred in this group since 1973, only 2 patients have had more attacks of angina pectoris that 1964. In contrast patients discontinuing therapy or replacing beta-pyridylcarbinol by other hypolipidemic drugs had a higher mortality.

(PDF emailed within 0-6 h: $19.90)

Accession: 041770834

Download citation: RISBibTeXText

PMID: 856228

DOI: 10.1016/0021-9150(77)90128-9

Related references

Treatment of hypercholesterolemia with beta-pyridylcarbinol. Experiences after long term treatment over 8 years. Medizinische Klinik 71(18): 768-774, 1976

Long-term plasmapheresis in coronary artery bypass grafting patients Report on two cases with familial hypercholesterolemia treated for more than six years. Koga, N , Inoue, N , Nakagawa, S ICAOT Press Publication; Therapeutic plasmapheresis (IX) : 268-272, 1991

Unusual but reversible hepatic lesions following long-term treatment with pyridylcarbinol for familial hypercholesterolemia. Klinische Wochenschrift 66(14): 647-650, 1988

Dextran sulfate cellulose ldl affinity apheresis in the treatment of severe familial hypercholesterolemia and non familial hyperlipoproteinemia a clinical report on twelve cases. Gotto, A M Jr , Et Al (Ed ) Treatment Of Severe Hypercholesterolemia in The Prevention Of Coronary Heart Disease; 2nd International Symposium, Munich, West Germany, June 29-30, 1989 Ix+274p S Karger Ag: Basel, Switzerland; New York, New York, Usa Illus 253-267, 1990

H.E.L.P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience. Artificial Organs 20(4): 303-310, 1996

Treatment of severe hypercholesterolemia with a combination of beta-sitosterol and lovastatin. Current Therapeutic Research 57(7): 497-505, 1996

Heterozygous familial hypercholesterolemia: a new point-mutation (1372del2) in the LDL-receptor gene which causes severe hypercholesterolemia. Human Mutation 14(4): 357, 1999

Dietary treatment and success rate of control in hypercholesterolemia patients treated with lipid lowering drugs: a multi-center study of current status on clinical control of hypercholesterolemia in China. Zhonghua Xin Xue Guan Bing Za Zhi 33(4): 372-375, 2005

Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. Journal of the American College of Cardiology 67(22): 2578-2589, 2017

Microvascular Function and Endothelial Progenitor Cells in Patients with Severe Hypercholesterolemia and the Familial Hypercholesterolemia Phenotype. Cardiology 137(4): 231-236, 2017

Greater preclinical atherosclerosis in treated monogenic familial hypercholesterolemia vs. polygenic hypercholesterolemia. Atherosclerosis 263: 405-411, 2017

Low-density lipoprotein apheresis versus lipid lowering drugs in the treatment of severe hypercholesterolemia: Four years' experience. Artificial Organs 20(4): 318-323, 1996

beta-VLDL hypercholesterolemia relative to LDL hypercholesterolemia is associated with higher levels of oxidized lipoproteins and a more rapid progression of coronary atherosclerosis in rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology 17(11): 2376-2382, 1997

Characteristics of children with familial and polygenic hypercholesterolemia referred through the national universal hypercholesterolemia screening a preliminary report. Atherosclerosis 263: E25-E26, 2017

Low density lipoprotein apheresis in the treatment of familial hypercholesterolemia Report of three cases. Journal de Pharmacie Clinique 14(2): 112-116, 1995